About Alaunos Therapeutics, Inc. - Common Stock (TCRT)
Alaunos Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies that leverage the power of the immune system. The company is particularly known for its research in T-cell receptor (TCR) therapy, which aims to harness genetically engineered T cells to target and eliminate tumor cells. Alaunos seeks to create personalized treatments tailored to the unique characteristics of each patient's cancer, with the goal of providing more effective and durable responses compared to conventional therapies. Through its advanced research and development efforts, Alaunos is committed to transforming cancer care and improving outcomes for patients. Read More
NEWPORT BEACH, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC (“PMGC Capital”), a wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB), today issued a public statement urging Alaunos Therapeutics, Inc. (NASDAQ: TCRT) to accept and act upon the term sheet previously facilitated through a leading Wall Street Bank.
NEWPORT BEACH, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC (“PMGC Capital,” “we,” “our,” or “us”), a wholly owned subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), today announced its planned filing of a Schedule 13D with the U.S. Securities and Exchange Commission disclosing beneficial ownership of common stock in Alaunos Therapeutics, Inc. (Nasdaq: TCRT).
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.
Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter financial results.
